DEA Rescheduling Hearing Excludes Cannabis Reform Advocates
Cannabis activists protest outside DEA headquarters as federal rescheduling hearing proceeds without reform supporters, raising questions about regulatory process fairness.
Cannabis reform advocates gathered outside Drug Enforcement Administration headquarters this week as federal officials conducted closed-door hearings on marijuana rescheduling without including legalization supporters. The proceedings, overseen by an agency administrative judge, feature only opponents of cannabis reform despite the potential for historic federal policy changes that could reshape the $30 billion legal cannabis market.
The exclusion of reform advocates from the formal hearing process highlights ongoing tensions between federal drug enforcement agencies and the cannabis industry. While the Biden administration initially proposed moving marijuana from Schedule I to Schedule III under the Controlled Substances Act, the current proceedings under Trump administration oversight appear to take a more restrictive approach to stakeholder input.
The lack of livestreaming access further compounds transparency concerns among industry participants who view federal rescheduling as critical to unlocking institutional investment and banking services. Cannabis companies currently face effective tax rates exceeding 70% due to Internal Revenue Code Section 280E, which prohibits business deductions for Schedule I substances. Rescheduling to Schedule III would eliminate these tax penalties and potentially add billions in value across public cannabis operators.
Major multi-state operators including Curaleaf, Green Thumb Industries, and Trulieve have built market capitalizations exceeding $1 billion while operating under current federal restrictions. However, limited access to traditional banking and capital markets continues constraining growth potential across the sector. The regulatory uncertainty surrounding federal scheduling creates ongoing volatility in cannabis equity valuations.
The hearing's composition suggests federal drug policy may remain restrictive regardless of growing state-level legalization momentum. Thirty-eight states now permit medical cannabis use while 24 allow adult recreational consumption, creating a $30 billion legal market that operates in federal legal limbo. The outcome of DEA proceedings will determine whether cannabis businesses gain access to standard financial services and federal tax treatment available to other industries.